Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)
Status:
Not yet recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
The study will investigate the effect of Dapagliflozin on atrial fibrillation (AF) burden. AF
burden will be defined as the percent of time spent in AF over a 2-week period, assessed by
noninvasive continuous heart rhythm monitoring at baseline and at 3 months, quality of life
(QOL) and validated echocardiographic indices of atrial myopathy. This knowledge will enable
us to study the therapeutic potential of SGLT2i as a novel adjunct treatment for patients
with DM and AF. Patients with paroxysmal AF (AF that terminates spontaneously or with
intervention within seven days of onset) and DM and randomize them to Dapagliflozin or
placebo. Continuous heart rhythm monitoring patch for AF burden will be used, measure of QOL
with the help of AF Effect on Quality-of-life survey and perform an echocardiogram with
measurement of left atrial volume index, left atrial strain and atrial tissue dopplers. All
measurements will be performed at baseline and at study completion. The central hypothesis is
that SGLT2i will lead to reduced AF burden that will translate into improvement in QOL, and
the underlying mechanism is improvement in atrial myopathy.